CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis

NOR-101Positive
AI Analysis

Summary

Aethlon Medical announces merger with North Immunology to advance NOR-101, a bispecific antibody targeting IL-13 and IL-18 for atopic dermatitis treatment. The oversubscribed deal values the combination at $180 million.

Importance:7/10
Sentiment:
0.70
mergeracquisitionbispecific antibodyatopic dermatitisIL-13IL-18inflammation
Related Companies
$MDCE

Read the original article

Published by PR Newswire Biotech on September 17, 2026 10:30 AM

Read Original